Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase – Here’s What Happened

Genmab A/S (NASDAQ:GMAB) shares saw unusually-high trading volume on Thursday . Approximately 470,144 shares traded hands during trading, a decline of 33% from the previous session’s volume of 705,920 shares.The stock last traded at $20.58 and had previously closed at $20.45.

Analyst Ratings Changes

Several brokerages have recently commented on GMAB. Morgan Stanley reaffirmed an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Redburn Atlantic began coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Trading Up 0.3 %

The stock has a market cap of $13.58 billion, a P/E ratio of 19.85, a P/E/G ratio of 0.64 and a beta of 0.99. The firm’s fifty day moving average is $23.40 and its 200 day moving average is $26.00.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The firm had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter last year, the business earned $0.47 EPS. Research analysts forecast that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. MML Investors Services LLC increased its holdings in shares of Genmab A/S by 5.4% during the 3rd quarter. MML Investors Services LLC now owns 73,261 shares of the company’s stock worth $1,786,000 after purchasing an additional 3,785 shares during the period. XTX Topco Ltd increased its stake in Genmab A/S by 116.4% in the third quarter. XTX Topco Ltd now owns 25,429 shares of the company’s stock valued at $620,000 after acquiring an additional 13,678 shares during the period. Two Sigma Advisers LP increased its stake in Genmab A/S by 84.1% in the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock valued at $14,996,000 after acquiring an additional 280,900 shares during the period. Quantinno Capital Management LP increased its stake in Genmab A/S by 56.8% in the third quarter. Quantinno Capital Management LP now owns 24,207 shares of the company’s stock valued at $590,000 after acquiring an additional 8,766 shares during the period. Finally, HighTower Advisors LLC bought a new stake in Genmab A/S in the third quarter valued at about $273,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.